Advanced search
Publication Cover
Expert Opinion on Drug Discovery Volume 2, 2007 - Issue 6
Submit an article Journal homepage
115
Views
7
CrossRef citations to date
0
Altmetric
Reviews

Use of RNA in drug design

Irene M Lagoja Katholieke Universiteit Leuven, Laboratory of Medicinal Chemistry, Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium +32 16 337396; +32 16 337340; [email protected]
, PhD &
Piet Herdewijn Katholieke Universiteit Leuven, Laboratory of Medicinal Chemistry, Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium +32 16 337396; +32 16 337340; [email protected]
, PhD
Pages 889-903 | Published online: 26 Jul 2007

Bibliography

  • GROSJEAN H (Ed.): Fine-Tuning of RNA Functions by Modification and Editing. Springer-Verlag Gmb. (2005).
  • DAVIDSON EA, ELLINGTON AD: Synthetic RNA circuits. Nat. Chem. Biol. (2007) 3(1):23-28.
  • GESTELAND, RF, CHECH TR, ATKINS JF (Eds): The RNA World. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1998).
  • SUTCLIFFE JA: Improving on nature: antibiotics that target the ribosome. Curr. Opin. Microbiol. (2005) 8(5):534-542.
  • PFISTER P, HOBBIE S, VICENS Q, BOTTGER EC, WESTHOF E: The molecular basis for A-site mutations conferring aminoglycoside resistance: relationship between ribosomal susceptibility and X-ray crystal structures. ChemBioChem (2003) 4:1078-1088.
  • OMURA S (Ed.): Macrolide Antibiotics. Academic Press, San Diego (2002).
  • SCHLUENZEN F, HARMS JM, FRANCESCHI F et al.: Structural basis for the antibiotic activity of ketolides and azalides. Structure (2003) 11:329-338.
  • TENSON T, LOVMAR M, EHRENBERG M: The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J. Mol. Biol. (2003) 330:1005-1014.
  • LIU M, DOUTHWAITE S: Resistance to the macrolide antibiotic tylosin is conferred by single methylations at 23S rRNA nucleotides G748 and A2058 acting in synergy. Proc. Natl. Acad. Sci. USA (2002) 99:14658-14663.
  • TU D, BLAHA G, MOORE PB, STEIZ TA: Structures of MLSBK antibiotics bound to mutated large ribosomal subunits provide a structural explanation for resistance. Cell (2005) 121:257-270.
  • COMARTIN DJ, BROWN ED: Non-ribosomal factors in ribosome subunit assembly are emerging targets for new antibacterial drugs. Curr. Opin. Pharmacol. (2006) 8:453-458.
  • TENSON T, MANKIN A: Antibiotics and the ribosome. Mol. Microbiol. (2006) 59(6):1664-1677.
  • SCHWALBE H, BUCK J, FÜRTIG B, NOESKE J, WÖHNERT J: Structures of RNA switches: insight into molecular recognition and tertiary structure. Angew. Chem. Int. Ed. (2007) 46:1212-1219.
  • BABITZKE P, GOLLNICK P: Posttranscription initiation control of tryptophan metabolism in Bacillus subtilis by the trp RNA-binding attenuation protein (TRAP), anti-TRAP, and RNA structure. J. Bacteriol. (2001) 183:5795-5802.
  • VITRASCHAK AG, RODIONOV DA, MIRONOV AA, GELFAND MS: Riboswitches, the oldest mechanism for the regulation of gene expression? Trends Genet. (2004) 20(1):44-50.
  • WINKLER WC: Riboswitches and the role of noncoding RNAs in bacterial metabolic control. Curr. Opin. Chem. Biol. (2005) 9:594-602.
  • SUDARSAN N, BARRICK, JE, BREAKER RR: Metabolite-binding RNA domains are present in the genes of eukaryotes. RNA (2003) 9:644-647.
  • TUCKER BJ, BREAKER RR: Riboswiches as versatile gene controle elements. Curr. Opin. Struct. Biol. (2005) 15:342-348.
  • BLOUNT KF, BREAKER RR: Riboswitches as antibacterial drug targets. Nat. Biotechnol. (2006) 24(12):1558-1564.
  • SUDARSAN N, HAMMOND MC, BLOCK K, WELZ R, BREAKER RR: Tandem riboswitch architectures exhibit complex gene control functions. Science (2006) 314:300-304.
  • SUDARSAN N, COHEN-CHALAMISH S, NAKAMURA S, EMILSSON GM, BREAKER RR: Thiamine pyrophosphate riboswitches are targets for the antimicrobial compound pyrithiamine. Chem. Biol. (2005) 12:1325-1335.
  • BLOUNT KF ,WANG JX, LIM J, SUDARSAN N, BREAKER RR: Antibacterial lysine analogs that target lysine riboswitches. Nat. Chem. Biol. (2007) 3(1):44-49.
  • BAYER TS, SMOLKE CD: Programmable ligand-controlled riboregulators of eukaryotic gene expression. Nat. Biotechnol. (2005) 23(3):337-343.
  • BAUER G, SUESS B: Engineered riboswitches as novel tools in molecular biology. J. Biotechnol. (2006) 124:4-11.
  • EBRAHIMI SES, WILTON AN, DOUGLAS KT: Unique binding site for bis-benzimidazoles on transfer RNA. Chem. Commun. (1997) 385-386.
  • BICHENKOVA EV, SADAT-EBRAHIMI SE, WILTON AN, O'TOOLE N, MARKS DS, DOUGLAS KT: Strong, specific, reversible binding ligands for transfer RNA: comparison by fluorescence and NMR spectroscopies with distamycin binding for a new structural class of ligand. Nucleosides & Nucleotides (1998) 17(9-11):1651-1665.
  • HECHT SM: In: Cancer Chemotherapeutic Agents. Foye WO (Ed.), American Chemical Society, Washington, DC (1995):369.
  • HOLMES CE, DUFF RJ, VAN DER MAREL GA, VAN BOOM J, HECHT SM: On the chemistry of RNA degradation by Fe.bleomycin. Bioorg. Med. Chem. (1997) 5:1235-1248.
  • ZAMAN GJR, MICHIELS PJA, VAN BOECKEL CAA: Targeting RNA: new opportunities to address drugless targets. Drug Discov. Today (2003) 8(7):297-306.
  • BANDYOPADHYAY S, NI J, RUGGIERO A et al.: A high-troughput drug screen targeted to the 5′-untranslated region of Alzheimer amyloid precursor protein mRNA. J. Biomol. Screen. (2006) 11(5):469-480.
  • ROGERS JT, RANDALL JD, CAHILL CM et al.: An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. (2002) 277(47):45518-45528.
  • WESTMARK PR, SHIN HC, WESTMARK CJ, SOLTANINASSAB SR, REINKE EK, MALTER JS: Decoy mRNAs reduce β-amyloid precursor protein mRNA in neuronal cells. Neurobiol. Aging (2006) 27(6):787-796.
  • HOWARD M, FRIZZELL RA, BEDWELL DM: Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med. (1996) 2:467-469.
  • BEDWELL DM, KAENJAK A, BEBOK Z et al.: Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat. Med. (1997) 3(11):1280-1284.
  • WILSCHANSKI M, YAHAV Y, YAACOV Y et al.: Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. (2003) 349:1433-1441.
  • WAGNER KR, HAMED S, HADLEY DW et al.: Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann. Neurol. (2001) 49:706-711.
  • KEELING KM, BROOKS DA, HOPWOOD JJ, LI P, THOMPSON JN, BEDWELL DM: Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of α-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum. Mol. Genet. (2001) 10:291-299.
  • HELIP-WOOLEY A, PARK MA, LEMONS RM, THOENE JG: Expression of CTNS alleles: subcellular localization and aminoglycoside correction in vitro. Mol. Genet. Metab. (2002) 75:128-133.
  • SLEAT DE, SOHAR I, GIN RM, LOBEL P: Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. Eur. J. Paediatr. Neurol. (2001) 5(Suppl.):A57-A62.
  • KEELING KM, BEDWELL DM: Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J. Mol. Med. (2002) 80(6):367-376.
  • MICHAEL K, TOR Y: Designing novel RNA binders. Chem. Eur. J. (1998) 4:2091.
  • KWON Y: Studies on the binding affinity of aminoglycoside antibiotics to the HIV-1 Rev responsive element for designing potential antiviral agents. J. Microbio. Biotechnol. (2006) 16(1):109-117.
  • KREBS A, LUDWIG V, BODEN O, GÖBEL MW: Targeting the HIV trans-activation responsive region-approaches towards RNA-binding drugs. ChemBioChem (2003) 4:972-978.
  • YANG M: Discoveries of Tat-TAR interaction inhibitors for HIV-1. Curr. Drug Targets Infect. Disord. (2005) 5(4):433-444.
  • ABOUL-FADL T: Antisense oligonucleotides: the state of art. Curr. Med. Chem. (2005) 12:2193-2214.
  • TAMM I: Antisense therapy in malignant diseases: status quo and quo vadis. Clin. Sci. (Lond) (2006) 110:427-442.
  • ABOUL-FADL T: Antisense oligonucleotide technologies in drug discovery. Expert Opin. Drug Discov. (2006) 1(4):285-288.
  • RUBENSTEIN M, TSUI P, GUINAN P: A review of antisense oligonucleotides in the treatment of human disease. Drugs of the Future (2004) 29(9):893-909.
  • THE VITRAVENE STUDY GROUP: A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. (2002) 133:467-474.
  • O'BRIEN S, MOORE JO, BOYD TE et al.: Randomized Phase III trial of fludarabine plus cyclophosphamide with or without Oblimersen Sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol. (2007) 25(9):1114-1120.
  • HERBST RS, FRANKEL SR: Oblimersen Sodium (genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin. Cancer Res. (2004) 10:s4245-s4248.
  • CHI KN, EISENHAUER E, FAZLI L et al.: A Phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer Inst. (2005) 97:1287-1296.
  • DEVI GR, BEER TM, CORLESS CL, ARORA V, WELLER DL, IVERSEN PL: In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin. Cancer Res. (2005) 11:3930-3938.
  • MOOK OR, BAAS F, DE WISSEL MB, FLUITER K: Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol. Cancer Therap. (2007) 6(3):833-843.
  • AUBERGER J, LOEFFLER-RAGG J, WURZER W, HILBE W: Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises. Curr. Cancer Drug Targets (2006) 6(4):271-294.
  • SWAYZE EE, SIWKOWSKI AM, WANCEWICZ EV et al.: Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. (2007) 35(2):687-700.
  • MELLO CC, CONTE D JR: Revealing the world of RNA interference. Nature (2004) 431:338-342.
  • DYKXHOORN D, LIEBERMAN J: The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu. Rev. Med. (2005) 56:401-423.
  • FIRE A, XU S, MONTGOMERY MK, KOSTAS SA, DRIVER SE, MELLO CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391:806-811.
  • VAUCHERET H, FAGARD M: Transcriptional gene silencing in plants: targets, inducers and regulators. Trends Genet. (2001) 17(1):29-35.
  • HAMMOND SM, CAUDY AA, HANNON GJ: Post-transcriptional gene silencing by doublestranded RNA. Nat. Rev. Genet. (2001) 2:110-119.
  • BUMCROT D, MONOHARAN M, KOTELIANSKY V, SAH DWY: RNAi therapeutics: a potential class of pharmaceutical drugs. Nat. Chem. Biol. (2006) 2(12):711-719.
  • GAITHER A, IOURGENKO V: RNA interference technologies and their use in cancer research. Curr. Opin. Oncol. (2007) 19:50-54.
  • KETZINEL-GILAD M, SHAUL Y, GALUN E: RNA interference for antiviral therapy. J. Gene Med. (2006) 8:933-950.
  • SAH DWY: Therapeutic potential of RNA interference for neurological disorders. Life Sci. (2006) 79:1773-1780.
  • KONG Q: RNAi: a novel strategy for the treatment of prion diseases. J. Clin. Investig. (2006) 116(12):3101-3103.
  • COREY DR: RNA learns from antisense. Nat. Chem. Biol. (2007) 3(1):8-11.
  • LI L-C, OKINO ST, ZHAO H et al.: Small dsRNAs induce transcriptional activation in human cells. Proc. Natl. Acad. Sci. USA (2006) 103(46):17337-17342.
  • CHAN JHP, LIM S, WONG WSF: Antisense oligonucleotides: from design to therapeutic application. Clin. Exp. Pharmacol. Physiol. (2006) 33:533-540.
  • SALEH M-C, VAN RIJ RP, HEKELE A et al.: The endocytic pathway mediates cell entry of dsRNA to induce RNAi silencing. Nat. Cell Biol. (2006) 8(8):793-802.
  • TOUB N, MALVY C, FATTAL E, COUVREUR P: Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed. Pharmacother. (2006) 60:607-620.
  • SANDRASAGRA A, LEONARD SA, TANG L et al.: Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev. (2002) 12:177-181.
  • LORENZ C, HADWIGER P, JOHN M, VORNLOCHER H-P, UNVERZAGT C: Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. (2004) 14(19):4975-4977.
  • HOLLINS AJ, FOX SP, AKHTAR S: Exogenous siRNA delivery: protocols for optimizing delivery to cells. Gene Silencing by RNA Interference (2005) 127-145.
  • YEKTA S, SHIH IH, BARTEL DP: MicroRNA-directed cleavage of HOXB8 mRNA. Science (2004) 304:594-596.
  • FILIPOWICZ W, JASKIEWICZ L, KOLB FA, PILLAI RS: Post-transcriptional gene silencing by siRNAs and miRNAs. Curr. Opin. Struct. Biol. (2005) 15:331-341.
  • GREGORY RI, SHIEKHATTAR R: MicroRNA biogenesis and cancer. Cancer Res. (2005) 65:3509-3512.
  • LECELLIER CH, DUNOYER P, ARAR K et al.: A cellular microRNA mediates antiviral defense in human cells. Science (2005) 308:557-560.
  • POY MN, ELIASSON L, KRUTZFELDT J et al.: A pancreatic islet-specific microRNA regulates insulin secretion. Nature (2004) 432:226-230.
  • DOSTIE J, MOURELATOS Z, YANG M, SHARMA A, DREYFUSS G: Numerous microRNPs in neuronal cells containing novel microRNAs. RNA (2003) 9:180-186.
  • ROBINS H, LI Y, PADGETT RW: Incorporating structure to predict microRNA targets. Proc. Natl. Acad. Sci. USA (2005) 102:4006-4009.
  • LIM LP, LAU NC, GARRETT-ENGELE P et al.: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 433:769-773.
  • WEILER J, HUNZIKER J, HALL J: Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther. (2006) 13:496-522.
  • LU J, GETZ G, MISKA EA et al.: MicroRNA expression profiles classify human cancers. Nature (2005) 435(7043):834-838.
  • ZENG Y, YI R, CULLEN BR: MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc. Natl. Acad. Sci. USA (2003) 100:9779-9784.
  • CALIN GA, SEVIGNANI C, DUMITRU CD et al.: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA (2004) 101:2999-3004.
  • IWAI N, NARABA H: Polymorphisms in human pre-miRNAs. Biochem. Biophys. Res. Commun. (2005) 331:1439-1444.
  • GANJU P, HALL J: Potential applications of siRNA for pain therapy. Expert Opin. Biol. Ther. (2004) 4:531-542.
  • LEE YS, KIM HK, CHUNG S, KIM KS, DUTTA A: Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the downregulation of putative targets during differentiation. J. Biol. Chem. (2005) 280:16635-16641.
  • LEAMAN D, CHEN PY, FAK J et al.: Antisensemediated depletion reveals essential and specific functions of microRNAs in Drosophila development. Cell (2005) 121:1097-1108.
  • CHENG AM, BYROM MW, SHELTON J, FORD LP: Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. (2005) 33(4):1290-1297.
  • DAVIS S, LOLLO B, FREIER S, ESAU C: Improved targeting of miRNA with antisense oligonucleotides. Nucleic Acids Res. (2006) 34(8):2294-2304.
  • ESAU C, DAVIS S, MURRAY SF et al.: miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. (2006) 3:87-98.
  • CHAN JA, KRICHEVSKY AM, KOSIK KS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. (2005) 65:6029-6033.
  • KRUETZFELDT J, RAJEWSKY N, BRAICH R et al.: Silencing of microRNAs in vivo with ‘antagomirs’. Nature (2005) 438(7068):685-689.
  • MA W, YU C: Intramolecular RNA replicase: possibly the first self replicating molecule in the RNA world. Origins of Life and Evolution of the Biosphere (2005) 36:413-420.
  • LILLEY DMJ: Structure, folding and mechanisms of ribozymes. Curr. Opin. Struct. Biol. (2005) 15:313-323.
  • YANG Y, WALSH CE: Spliceosome-mediated RNA transsplicing. Mol. Ther. (2005) 12:1006-1012.
  • BECILACQUA PC, YAJIMA R: Nucleobase catalysis in ribozyme mechanism. Curr. Opin. Chem. Biol. (2006) 10:455-464.
  • BAGHERI S, KASHANI-SABET M: Ribozymes in the age of molecular therapeutics. Curr. Mol. Med. (2004) 4(5):489-506.
  • MANSFIELD SG, CHAO H, WALSH CE: RNA repair using spliceosome-mediated RNA trans-splicing. Trends Mol. Med. (2004) 10:263-268.
  • KALAVRIZIOTI D, VOUREKAS A, STAMATOPOULOU V et al.: RNA-mediated therapeutics: from gene inactivation to clinical application. Curr. Topics Med. Chem. (2006) 6(16):1737-1758.
  • SULLENGER BA: Targeted genetic repair: an emerging approach to genetic therapy. J. Clin. Invest. (2003) 112:310-311.
  • SCHUBERT S, KURRECK J: Ribozyme- and deoxyribozymestrategies for medical applications. Curr. Drug Targets (2004) 5:667-681.
  • BENITEZ-HESS ML, ALVAREZ-SALAS LM: Utilization of ribozymes as antiviral agents. Letters Drug Design & Discovery (2006) 3(6):390-404.
  • CUNNINGHAM AP, LOVE WK, ZHANG, RW, ANDREWS LG, TOLLEFSBOL T: Telomerase inhibition in cancer therapeutics: molecular-based approaches. Curr. Med. Chem. (2006) 13(24):2875-2888.
  • LEWIN AS, HAUSWIRTH WW: Ribozyme gene therapy: applications for molecular medicine. Trends Mol. Med. (2001) 7:221-228.
  • BOK D: Gene therapy of retinal dystrophies: achievements, challenges and prospects. Novartis Foundation Symposium (2004) 255(Retinal Dystrophies):4-16.
  • KIANG AS, PALFI A, ADER M et al.: Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation independent approach. Mol. Ther. (2005) 12:555-561.
  • GORBATYUK MS, PANG JJ, THOMAS J JR, HAUSWIRTH WW, LEWIN AS: Knockdown of wild-type mouse rhodopsin using an AAV vectored ribozyme as part of an RNA replacement approach. Mol. Vis. (2005) 11:648-656.
  • MACPHERSON JL, BOYD MP, ARNDT AJ et al.: Long-term survival and concomitant gene expression of ribozymetransduced CD4+ T-lymphocytes in HIV-infected patients. J. Gene Med. (2005) 7:552-564.
  • CORDELIER P, KULLOWSKY JW, KO C et al.: Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5. Gene Ther. (2004) 11(22):1627-1637.
  • FOSTER GR: Past, present, and future hepatitis C treatments. Seminars in Liver Disease (2004) 24(2):97-104.
  • LI X, KUANG E, DAI W, ZHOU B, YANG F: Efficient inhibition of hepatitis B virus replication by hammerhead ribozymes delivered by hepatitis delta virus. Virus Res. (2005) 114(1-2):126-132.
  • KOBAYASHI H, ECKHARDT SG, LOCKRIDGE JA et al.: Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. (2005) 56(4):329-336.
  • WENG DE, MASCI PA, RADKA SF et al.: A Phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Mol. Cancer Ther. (2005) 4:948-955.
  • Suppression of EGFRvIII-mediated proliferation and tumorigenesis of breast cancer cells by ribozyme. Int. J. Cancer (2003) 104(6):716-721.
  • RIMMELE M: Nucleic acid aptameres as tools and drugs: recent developments. ChemBioChem (2003) 4:963-971.
  • HERMANN T, PATEL DJ: Adaptive recognition by nucleic acid aptamers. Science (2000) 287(5454):820-825.
  • BEREZOVSKI M, DRABOVICH A, KRYLOVA SM et al.: Nonequilibrium capillary electrophoresis of equilibrium mixtures: a universal tool for development of aptamers. J. Am. Chem. Soc. (2005) 127:3165-3171.
  • GOLDEN MC, COLLINS BD, WILLIS MC, KOCH TH: Diagnostic potential of PhotoSELEX-evolved ssDNA aptamers. J. Biotechnol. (2000) 81:167-178.
  • VATER A, JAROSCH F, BUCHNER K, KLUSSMANN S: Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX. Nucleic Acids Res. (2003) 31:el30-e130.
  • UHLMANN E, PEYMAN A, RYTE A, SCHMIDT A, BUDECKE E: Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression. Methods Enzymol. (2000) 313:268-284.
  • BURMEISTER PE, LEWIS SD, SILVA RF et al.: Direct in vitro selection of a 2(-O-methyl) aptamer to VEGF. Chem. Biol. (2005) 12:25-33.
  • BASSETT SE, FENNEWALD SM, KING DJ et al.: Combinatorial selection and edited combinatorial selection of phosphorothioate aptamers targeting human NF-κB RelA/p50 and RelA/RelA. Biochemistry (2004) 43:9105-9115.
  • CHELLISERRYKATTIL J, ELLINGTON AD: Evolution of a T7 RNA polymerase variant that transcribes 2(-O-methyl) RNA. Nat. Biotechnol. (2004) 22:1155-1160.
  • SCHMIDT KS, BORKOWSKI S, KURRECK J et al.: Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res. (2004) 32(19):5757-5765.
  • EULBERG D, KLUSSMANN S: Spiegelmers: biostable aptamers. ChemBioChem (2003) 4(10):979-983.
  • MASCINI M, PAPAMICHAEL K, MEVOLA I, PRAVDA, M, GUILBAULT GG: Ghrelin detection using spiegelmer-capture molecules. Analyt. Lett. (2007) 40(3):403-430.
  • NIMJEE SM, RUSCONI CP, HARRINGTON RA, SULLENGER BA: The potential of aptamers as anticoagulants. Trends Cardiovasc. Med. (2005) 15:41-45.
  • REYDERMAN L, STAVCHANSKY S: Pharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in rats. Pharm. Res. (1998) 15:904-910.
  • DE SMIDT PC, LE DOAN T, DE FALCO S, VAN BERKEL TJ: Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucleic Acids Res. (1991) 19:4695-4700.
  • HEALY JM, LEWIS SD, KURZ M et al.: Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res. (2004) 21:2234-2246.
  • FAROKHZAD OC, JON S, KHADEMHOSSEINI A, TRAN TN, LAVAN DA, LANGER R: Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. (2004) 64:7668-7672.
  • LEE JF, STOVALL GM, ELLINGTON AD: Aptamer therapeutics advance. Curr. Opin. Biol. (2006) 10:282-289.
  • SIDDIQUI MA, KEATING GM: Pegaptanib: in exudative age-related macular degeneration. Drugs (2005) 65:1571-1579.
  • NIMJEE SM, RUSCONI CP, SULLENGER BA: Aptameres: an emerging class of therapeutics. Annu. Rev. Med. (2005) 56:555-583.
  • BOCK LC, GRIFFIN LC, LATHAM JA, VERMAAS EH, TOOLE JJ: Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature (1992) 355:564-566.
  • RUSCONI CP, ROBERTS JD, PITOC GA et al.: Antidote mediated control of an anticoagulant aptamer in vivo. Nat. Biotechnol. (2004) 22:1423-1428.
  • DEY AK, GRIFFITHS C, LEA SM, JAMES W: Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. RNA (2005) 11:873-884.
  • MISONO TS, KUMAR PK: Selection of RNA aptamers against human influenza virus hemagglutinin using surface plasmon resonance. Anal. Biochem. (2005) 342:312-317.
  • BURKE DH, SCATES L, ANDREWS K, GOLD L: Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase. J. Mol. Biol. (1996) 264:650-666.
  • HICKE BJ, STEPHENS AW: Escort aptamers: a delivery service for diagnosis and therapy. J. Clin. Invest. (2000) 106:923-928.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.